Indenture Agreements in the Biotechnology Industry
224 Contracts & Agreements
- AbbVie Inc. (8 contracts)
- Acorda Therapeutics (3)
- AGENUS INC (1)
- ALNYLAM PHARMACEUTICALS, INC. (2)
- AMARIN CORP PLC (3)
- Amgen Inc. (5)
- AMICUS THERAPEUTICS, INC. (1)
- Apellis Pharmaceuticals, Inc. (1)
- Arsanis, Inc. (1)
- ARYA Sciences Acquisition Corp II (1)
- Avid Bioservices, Inc. (3)
- Beam Therapeutics Inc. (4)
- Biogen Inc. (6)
- BIOMARIN PHARMACEUTICAL INC (9)
- BridgeBio Pharma, Inc. (2)
- CATALYST BIOSCIENCES, INC. (1)
- Celldex Therapeutics, Inc. (1)
- Clovis Oncology, Inc. (6)
- CohBar, Inc. (2)
- Coherus BioSciences, Inc. (1)
- CTI BIOPHARMA CORP (2)
- Cytokinetics, Incorporated (3)
- Dermira, Inc. (2)
- Dicerna Pharmaceuticals Inc (1)
- DYNAVAX TECHNOLOGIES CORP (1)
- Emergent BioSolutions Inc. (2)
- ENZON PHARMACEUTICALS, INC. (1)
- Esperion Therapeutics, Inc. (1)
- EXACT SCIENCES CORP (5)
- Exelixis (2)
- FENNEC PHARMACEUTICALS INC. (1)
- Flexion Therapeutics Inc (2)
- Frequency Therapeutics, Inc. (1)
- Gilead Sciences (8)
- Global Blood Therapeutics, Inc. (2)
- Gossamer Bio, Inc. (1)
- HALOZYME THERAPEUTICS INC (3)
- IMMUCELL CORP (1)
- IMMUNOGEN INC (1)
- Incyte (4)
- INOVIO PHARMACEUTICALS, INC. (1)
- INSMED Inc (3)
- INTERCEPT PHARMACEUTICALS, INC. (6)
- INTREXON CORP (2)
- Invitae Corp (6)
- IONIS PHARMACEUTICALS INC (5)
- IRONWOOD PHARMACEUTICALS INC (5)
- Kadmon Holdings, Inc. (1)
- Karyopharm Therapeutics Inc. (1)
- Keros Therapeutics, Inc. (1)
- LEXICON PHARMACEUTICALS, INC. (1)
- Ligand Pharmaceuticals Incorporated (3)
- MANNKIND CORP (6)
- MERRIMACK PHARMACEUTICALS INC (3)
- Mersana Therapeutics, Inc. (1)
- Mirum Pharmaceuticals, Inc. (1)
- Natera, Inc. (1)
- NEUROCRINE BIOSCIENCES INC (2)
- NORTHWEST BIOTHERAPEUTICS INC (3)
- NOVAVAX INC (2)
- Opko Health, Inc. (4)
- PDL BIOPHARMA, INC. (12)
- PROGENITY, INC. (5)
- Protalix BioTherapeutics, Inc. (6)
- PTC THERAPEUTICS, INC. (2)
- Radius Health, Inc. (3)
- Regeneron Pharmaceuticals (3)
- Retrophin, Inc. (3)
- ROCKET PHARMACEUTICALS, INC. (9)
- Sarepta Therapeutics, Inc. (2)
- Sorrento Therapeutics, Inc. (2)
- Spectrum Pharmaceuticals, Inc. (1)
- T2 Biosystems, Inc. (1)
- Translate Bio, Inc. (1)
- United Therapeutics Corp (1)
- Verastem, Inc. (3)
- Vertex Pharmaceuticals Inc (5)
- Zai Lab Ltd (1)
- Zymeworks Inc. (1)
- Second Supplemental Indenture, dated as of March 12, 2024, between Biora Therapeutics, Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee (PROGENITY, INC., Filed With SEC on April 1, 2024)
- First Supplemental Indenture, dated as of December 19, 2023, between Biora Therapeutics, Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee (PROGENITY, INC., Filed With SEC on April 1, 2024)
- Indenture, dated as of March 12, 2024, by and between the Company and U.S. Bank Trust Company, National Association, as Trustee (Avid Bioservices, Inc., Filed With SEC on March 14, 2024)
- Form of Supplemental Indenture, to be dated as of the Closing Date, between the Company, the guarantors party thereto and GLAS Trust Company LLC (PROGENITY, INC., Filed With SEC on March 11, 2024)
- Supplemental Indenture No. 10, dated February 26, 2024, between AbbVie Inc. and U.S. Bank Trust Company, National Association, as trustee (AbbVie Inc., Filed With SEC on February 26, 2024)
- Indenture, dated January 9, 2024, by and between OPKO Health, Inc. and U.S. Bank Trust Company, National Association, as Trustee (Opko Health, Inc., Filed With SEC on January 9, 2024)
- Indenture, to be dated as of the Closing Date, between the Company and GLAS Trust Company LLC (PROGENITY, INC., Filed With SEC on December 18, 2023)
- Third Amendment of Indenture of Lease for Premises Located in Portland, Maine between the Company and TVP, LLC dated as of November 14, 2023 (IMMUCELL CORP, Filed With SEC on November 16, 2023)
- Second Supplemental Indenture, dated as of November 8, 2023, between Intercept Pharmaceuticals, Inc. and U.S. Bank Trust Company, National Association (INTERCEPT PHARMACEUTICALS, INC., Filed With SEC on November 8, 2023)
- Third Supplemental Indenture, dated as of November 8, 2023, between Intercept Pharmaceuticals, Inc., and U.S. Bank Trust Company, National Association (INTERCEPT PHARMACEUTICALS, INC., Filed With SEC on November 8, 2023)
- Ninth Supplemental Indenture, dated as of September 14, 2023, between the Company and Computershare Trust Company, National Association, as successor to Wells Fargo Bank, National... (Gilead Sciences, Filed With SEC on September 14, 2023)
- First Supplemental Indenture, dated August 22, 2023, among Invitae Corporation, the guarantor parties thereto and U.S. Bank Trust Company, National Association, as trustee and... (Invitae Corp, Filed With SEC on August 23, 2023)
- Indenture, dated as of June 12, 2023, by and between the Company and U.S. Bank Trust Company, National Association, as Trustee (IONIS PHARMACEUTICALS INC, Filed With SEC on June 12, 2023)
- Indenture, dated as of April 17, 2023, between Mirum Pharmaceuticals, Inc. and U.S. Bank Trust Company, National Association, as trustee (Mirum Pharmaceuticals, Inc., Filed With SEC on April 17, 2023)
- Indenture, dated as of March 7, 2023, between Invitae Corporation, the guarantor parties thereto and U.S. Bank Trust Company, National Association, as trustee and collateral agent (Invitae Corp, Filed With SEC on March 8, 2023)
- Form of New Notes Indenture (Invitae Corp, Filed With SEC on March 1, 2023)
- Fourth Supplemental Indenture, dated March 1, 2023, between the Company and U.S. Bank National Association, as Trustee (including the form of 2.00% Convertible Senior Notes due... (EXACT SCIENCES CORP, Filed With SEC on March 1, 2023)
- Indenture, dated as of December 20, 2022, between Novavax, Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee (NOVAVAX INC, Filed With SEC on December 21, 2022)
- Indenture, dated as of September 15, 2022, between the Registrant (ALNYLAM PHARMACEUTICALS, INC., Filed With SEC on October 27, 2022)
- First Supplemental Indenture, dated as of October 5, 2022, between Global Blood Therapeutics, Inc. and U.S. Bank Trust Company, National Association, as trustee (Global Blood Therapeutics, Inc., Filed With SEC on October 5, 2022)
- Indenture, dated as of September 16, 2022, by and between Sarepta Therapeutics, Inc. and U. S. Bank Trust Company, National Association (including the form of the 1.250%... (Sarepta Therapeutics, Inc., Filed With SEC on September 19, 2022)
- Indenture, dated as of September 15, 2022, between Alnylam Pharmaceuticals, Inc. and The Bank of New York Mellon, as trustee (ALNYLAM PHARMACEUTICALS, INC., Filed With SEC on September 16, 2022)
- Indenture, dated August 18, 2022 between Halozyme Therapeutics, Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee (HALOZYME THERAPEUTICS INC, Filed With SEC on August 18, 2022)
- Indenture, dated as of August 16, 2022, between Cerevel Therapeutics Holdings, Inc. and U.S. Bank Trust Company, National Association, as trustee (ARYA Sciences Acquisition Corp II, Filed With SEC on August 16, 2022)
- Second Supplemental Indenture, dated August 15, 2022, by and between Radius Health, Inc. and Wilmington Trust, National Association, as trustee (Radius Health, Inc., Filed With SEC on August 15, 2022)
- Indenture, dated as of July 6, 2022, between Cytokinetics, Incorporated and U.S. Bank Trust Company, National Association, as trustee (Cytokinetics, Incorporated, Filed With SEC on July 6, 2022)
- Consent Under and Amendment No. 4 to Indenture, dated June 3, 2022, by and among Sorrento Therapeutics, Inc., Scilex Pharmaceuticals Inc., U.S. Bank Trust Company, National... (Sorrento Therapeutics, Inc., Filed With SEC on June 3, 2022)
- Second Supplemental Indenture, dated March 11, 2022, between the Company and U.S. Bank Trust Company, National Association, as Trustee (including the form of 2.25% Convertible... (Retrophin, Inc., Filed With SEC on March 11, 2022)
- Amendment No. 3 to Indenture of Lease, between Massachusetts Institute of Technology and Beam Therapeutics Inc., dated August 24, 2021 (Beam Therapeutics Inc., Filed With SEC on February 28, 2022)
- Amendment No. 2 to Indenture of Lease, between Massachusetts Institute of Technology and Beam Therapeutics Inc., dated November 17, 2020 (Beam Therapeutics Inc., Filed With SEC on February 28, 2022)
- Amendment No. 1 to Indenture of Lease, between Massachusetts Institute of Technology and Beam Therapeutics Inc., dated April 14, 2020 (Beam Therapeutics Inc., Filed With SEC on February 28, 2022)
- First Supplemental Indenture, dated as of December 22, 2021, by and between the Company and U.S. Bank National Association, as Trustee (NEUROCRINE BIOSCIENCES INC, Filed With SEC on February 11, 2022)
- Indenture, dated as of December 17, 2021, between Global Blood Therapeutics, Inc. and U.S. Bank National Association, as trustee (Global Blood Therapeutics, Inc., Filed With SEC on December 17, 2021)
- First Supplemental Indenture, dated as of November 19, 2021, by and between Flexion Therapeutics, Inc. and Wells Fargo Bank, National Association, as trustee (Flexion Therapeutics Inc, Filed With SEC on November 19, 2021)
- First Supplemental Indenture, dated as of November 9, 2021, by and between Kadmon Holdings, Inc. and U.S. Bank National Association, as Trustee (Kadmon Holdings, Inc., Filed With SEC on November 9, 2021)
- Indenture of Lease by and between the Registrant and Revolution Labs Owner, LLC, dated September 7, 2021 (Keros Therapeutics, Inc., Filed With SEC on November 4, 2021)
- Third Supplemental Indenture, dated as of August 24, 2021, by and among Protalix BioTherapeutics, Inc., the guarantors party hereto and The Bank of New York Mellon Trust Company,... (Protalix BioTherapeutics, Inc., Filed With SEC on August 26, 2021)
- First Supplemental Indenture, dated as of August 17, 2021, between Intercept Pharmaceuticals, Inc. and U.S. Bank National Association, as trustee and as collateral agent (INTERCEPT PHARMACEUTICALS, INC., Filed With SEC on August 23, 2021)
- Indenture, dated as of August 17, 2021, between Intercept Pharmaceuticals, Inc. and U.S. Bank National Association, as trustee (INTERCEPT PHARMACEUTICALS, INC., Filed With SEC on August 23, 2021)
- Second Supplemental Indenture, dated as of May 13, 2021, by and between the Company and Wells Fargo Bank, National Association (INSMED Inc, Filed With SEC on May 13, 2021)
